---
title: treatment of primary myelofibrosis (PMF)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[primary myelofibrosis (PMF)]]

# treatment of primary myelofibrosis (PMF) #ðŸš§ æ–½å·¥ä¸­

## treatment of primary myelofibrosis (PMF)Â 

(Am J HematolÂ 2021;96:145)

â€¢ In absence of adverse prognostic factors (eg, anemia or sx) â†’ no treatment

â€¢ Allogeneic HSCT only potential cure â†’ consider in young Pts w/ high-risk disease

â€¢ Supportive care:Â **transfusions;**Â ESA if Epo <500 (risk â†‘ splenomegaly); consider androgens vs. immunomodulatory agents (eg, lenalidomide) + prednisone; hydroxyurea; ? splenectomy if refractory to transfusions, failed chemoRx, painful splenomegaly

## JAK inh:
- **ruxo**-LI-tinib (JAK1/2)
â†“ sx, â†“ splenomegaly, â†‘ survival; preferredÂ (NEJMÂ 2012;366:787 & 799);
- fedratinib
(JAK2;Â JAMA Oncol2015;1:643)
- pacritinib & momelotinib under study


## Median survival
* ~6 yÂ (JCOÂ 2012;30:2981)
* transformation into AML occurs at a rate of ~8%/y

